-
Lecanemab, also known by the brand name Leqembi, is not a cure for Alzheimer’s disease. But research indicates the new medication can significantly slow its progression.
-
This week’s federal approval of a medication called lecanemab — the brand name for which is Leqembi — represents a watershed moment for treating Alzheimer’s disease.
-
Harvard University's Daniel Lieberman looks at exercise from an evolutionary point of view, concluding that we evolved to limit our physical activity where possible, saving it for survival activities.